Patient Counseling for Finerenone

Article Sidebar

PDF
Published: Sep 19, 2023
DOI: https://doi.org/10.59793/ijcp.v34i4.598
Keywords:
Aldosterone antagonist, chronic kidney disease, diabetic kidney disease, mineralocorticoid receptor antagonist, patient-centered care, person-centered care, type 2 diabetes

Main Article Content

Sanjay Kalra
Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
Banshi Saboo
Dept. of Diabetology, Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India
Beatrice Anne
Dept. of Endocrinology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
Mathew John
Dept. of Endocrinology, Providence Endocrine and Diabetes Specialty Centre, Trivandrum, Kerala, India
Pradip Dalwadi
Dept. of Endocrinology, Pratham Diabetes and Endocrine Centre, Surat, Gujarat, India
Shehla Shaikh
Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Abstract

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, which is used to retard the progression of chronic kidney disease in persons with type 2 diabetes. This communication describes the various aspects of patient counseling needed to ensure safe and effective usage of the molecule. It utilizes the 5C checklist: Confirmation of clinical indication; Caveats and contraindications; Concerns and checkpoints; Caution and use with concomitant medication; and Constraints and cost, to create a simple, yet comprehensive tool for clinical use.

Article Details

How to Cite
Sanjay Kalra, Banshi Saboo, Beatrice Anne, Mathew John, Pradip Dalwadi, & Shehla Shaikh. (2023). Patient Counseling for Finerenone. Indian Journal Of Clinical Practice, 34(4), 28–30. https://doi.org/10.59793/ijcp.v34i4.598
Issue
Vol. 34 No. 4 (2023)
Section
Brief Communication
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

1 2 3 4 > >>